Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Ketamine and psilocybin are the two most researched psychedelic-assisted therapies for depression, and this comparison of ketamine vs psilocybin comparing two psychedelic-assisted therapies for depression breaks down how each drug works in the brain, how legal each one is, and how a course of treatment is structured. Both produce rapid antidepressant effects in clinical trials, but the two diverge everywhere else. Ketamine has been an FDA-approved anesthetic since 1970 and is prescribed off-label for depression nationwide. Psilocybin remains a Schedule I controlled substance under federal law. Oregon legalized supervised psilocybin services in 2023, and a handful of cities have deprioritized enforcement, but access outside that state stays limited.
Quick Answer
Ketamine offers faster access nationwide, with relief often starting within hours and treatment available through off-label prescription or the FDA-approved nasal spray esketamine (Spravato), but it typically requires repeated sessions to maintain results. Psilocybin needs only one or two long guided sessions and its effects can last weeks to months in trial data, but it remains federally illegal outside Oregon's licensed service centers and a handful of cities that have deprioritized enforcement. Choose based on which trade-off matters more to you: ketamine's frequent dosing and broad legal access, or psilocybin's fewer sessions and current legal limits.
Mechanism Comparison
Ketamine and psilocybin act on different receptor systems, which explains why the subjective experience and the treatment protocols for each look so different.
Ketamine primarily blocks NMDA glutamate receptors, triggering a glutamate surge that activates the BDNF-mTOR pathway and drives rapid synaptogenesis. For a full breakdown of that process, see how ketamine works in the brain and the role of BDNF in neuroplasticity. Psilocybin, once converted to psilocin in the body, activates 5-HT2A serotonin receptors, disrupting default mode network activity and promoting neuroplasticity through molecular cascades that overlap with ketamine's in some respects but diverge in timing and duration.
Clinical Evidence
Ketamine has the larger and older evidence base. According to a meta-analysis by Kishimoto and colleagues, more than 40 randomized controlled trials have tested single-dose ketamine for depression, with pooled results confirming rapid antidepressant effects across nearly three decades of research involving thousands of patients. For how those effects compare with standard antidepressants, see ketamine vs SSRIs.
Psilocybin's trial record is smaller but has grown more rigorous. In the COMPASS Pathways Phase IIb trial published in the New England Journal of Medicine, a single 25 mg dose of psilocybin produced a significant reduction in depression severity compared with lower doses. SeparatelyDavis and colleagues at Johns Hopkins reported that two psilocybin sessions produced large, rapid decreases in depression scores, with 71 percent of participants showing a greater than 50 percent reduction in symptoms at four weeks. According to the National Institute of Mental Health, both approaches are part of a broader research effort into fast-acting depression treatments that work differently than traditional antidepressants.
Treatment Protocol
The two therapies also differ sharply in how treatment is structured and how often sessions happen.
The biggest practical difference is frequency. Ketamine typically starts with six sessions over two to three weeks, then moves to maintenance dosing every two to eight weeks, since effects tend to fade within days to weeks. Psilocybin trials suggest that one or two longer sessions, each requiring six to eight hours including preparation, can produce effects lasting weeks to months, though long-term durability data beyond a year remains limited. For more on how a typical ketamine series is structured, see ketamine-assisted psychotherapy.
Accessibility and Legal Status
Legal status is the clearest dividing line between the two therapies.
Ketamine is a Schedule III substance, meaning it has an accepted medical use and lower abuse potential under federal law, and the FDA has approved esketamine (marketed as Spravato) specifically for treatment-resistant depression. See esketamine as an FDA-approved option for how it compares to generic ketamine. Psilocybin remains Schedule I federally, meaning federal law does not currently recognize an accepted medical use, though it holds FDA breakthrough therapy designation and is legally available through licensed service centers in Oregon. For a broader look at where ketamine stands legally by state, see is ketamine legal.
Ketamine: What Works in Its Favor
- Legal nationwide as an off-label prescription or as the FDA-approved nasal spray esketamine
- Effects often begin within hours of the first session
- Decades of clinical use as an anesthetic give providers a long safety track record
Ketamine: What to Weigh
- Requires six initial sessions over two to three weeks, then ongoing maintenance dosing
- Acute effects include dissociation, nausea, and a temporary rise in blood pressure
- Frequent, unsupervised use carries a risk of tolerance, dependence, and bladder toxicity
Psilocybin: What Works in Its Favor
- As few as one or two guided sessions can produce effects lasting weeks to months
- Minimal addiction potential and no known organ toxicity
- Holds FDA breakthrough therapy designation for depression
Psilocybin: What to Weigh
- Remains Schedule I under federal law, limiting legal access to Oregon's licensed service centers and a few cities that have deprioritized enforcement
- Each session requires six to eight hours, including preparation
- Contraindicated for people with psychotic disorders or a family history of psychosis, and acute sessions can include anxiety or psychologically challenging experiences
Questions to Ask Before Choosing Ketamine or Psilocybin Therapy
- Is this therapy legally available where I live, or would I need to travel?
- Am I looking for a treatment I can start now, or can I wait for a longer, less frequent protocol?
- Do I have a personal or family history of psychosis that would rule out psilocybin?
- Can I commit to a maintenance schedule of ketamine sessions every few weeks?
- Have I discussed either option with a prescriber or licensed provider who can screen for contraindications?
Key Takeaway
Ketamine is the more accessible option today: it's legal nationwide, has decades of safety data, and can start working within hours, but it needs repeated sessions to keep working. Psilocybin needs far fewer sessions and its effects may last longer, but federal law still restricts where you can legally receive it.
Helpful next step
Browse more head-to-head comparisons of ketamine against other depression treatments to see where it fits your situation.
Learn More
Talk with a licensed provider about whether ketamine therapy fits your depression treatment plan.
Frequently Asked Questions
Clinical trials have tested each independently, and there is no published research on combining them in the same treatment plan. Talk with a prescriber before combining any psychedelic-assisted therapies.
Federally, psilocybin is a Schedule I controlled substance. Oregon is the only state with licensed, supervised psilocybin services as of 2026, and a small number of cities have deprioritized enforcement without creating a legal service model. Check your state's current law before seeking treatment.
Ketamine tends to produce noticeable relief within hours of the first session. Psilocybin's single or two-session protocols in trials have also shown rapid effects, but the treatment day itself is longer, often six to eight hours including preparation.
Ketamine is classified as Schedule III, reflecting an accepted medical use as an FDA-approved anesthetic since 1970. Psilocybin remains Schedule I federally, meaning federal law does not currently recognize an accepted medical use, even though it holds FDA breakthrough therapy designation for depression.
Verdict
Ketamine is currently the only legal and widely accessible psychedelic-adjacent treatment for depression, with robust clinical evidence and established infrastructure. Psilocybin shows extraordinary promise in clinical trials, with potentially longer-lasting effects from fewer sessions, but remains available only in limited settings. For patients seeking treatment now, ketamine is the practical choice. Psilocybin may offer advantages when broader access becomes available.
Share
Related Reading
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.